Clinical Utility of Liquid Biopsy as a tool to assess the evolution of brigatinib treated patients with non-small cell lung cancer with EML4-ALK translocation: an exploratory study (CUBIK)
This clinical trial is testing a targeted medicine called brigatinib (brand name Alunbrig) for adults with ALK-positive non-small cell lung cancer. In this type of cancer, an altered gene called ALK makes cancer cells grow and spread. Brigatinib is a daily tablet designed to block this signal and stop the cancer. The trial also explores whether simple blood tests, called 'liquid biopsies', can track how the cancer responds to the medicine over time. Liquid biopsies look for tiny bits of tumour DNA in the blood. If successful, they could give doctors important information without the need for painful tissue biopsies. Doctors will measure how much tumours shrink, whether the drug helps treat cancer that has spread to the brain, and how long it keeps the cancer under control. Patients will have regular check-ups, scans, and blood tests to monitor their health.
At a glance
What is this study about?
Lung cancer has several different forms. In some people, a specific change in their genes—known as an ALK gene alteration—causes non-small cell lung cancer to grow and spread. Fortunately, doctors have developed targeted medicines designed specifically to block these faulty signals and slow down tumour growth.
This study, called the CUBIK trial, is looking at a targeted tablet called brigatinib (Alunbrig). Researchers want to find out how effective brigatinib is at shrinking tumours and keeping the cancer from growing, including whether it can treat cancer that may have spread to the brain. They also want to make sure the drug is safe and manageable for patients to take on a daily basis.
An exciting part of this trial is the use of 'liquid biopsies'. Traditionally, doctors must take a piece of tumour tissue with a needle to understand how cancer is changing. A liquid biopsy uses a routine blood sample instead to detect tiny pieces of cancer DNA floating in the blood. If successful, this could help doctors spot changes in the cancer much sooner and tailor treatments without needing invasive procedures.
Key takeaways
- Tests the targeted tablet brigatinib (Alunbrig) for ALK-positive non-small cell lung cancer.
- Uses simple blood tests (liquid biopsies) to monitor how cancer DNA changes over time.
- Aims to shrink tumours in the body and brain and keep cancer under control.
- Open to adults aged 18 and older with confirmed ALK-positive lung cancer.
- Involves daily tablets at home and regular hospital visits for scans and check-ups over two years.
Who may be eligible?
This trial is open to adults aged 18 and older who have been diagnosed with advanced non-small cell lung cancer. To be eligible, tests on your cancer must confirm that you have a specific genetic change known as an ALK alteration (ALK-positive lung cancer).
Both men and women can join. You will need to be well enough to carry out daily activities and be able to swallow tablets every day. Your doctor will also check that your heart, liver, and kidneys are working well enough to safely process the medication.
You may not be able to take part if you have certain other serious medical conditions or severe lung inflammation not caused by cancer. Your oncology team will look closely at your medical history and previous treatments to see if this study is safe and suitable for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with non-small cell lung cancer.
- My cancer has been confirmed as ALK-positive by laboratory tests.
- I am able to swallow tablets every day.
- I am willing and able to attend regular hospital appointments for scans and blood tests.
What does participation involve?
If you take part, you will be given brigatinib tablets to take by mouth once a day at home. You will visit the hospital clinic regularly for check-ups, especially in the first few months. During these visits, doctors will check your general health, ask about any symptoms, take blood samples for liquid biopsies, and arrange imaging scans (such as CT or MRI scans) to see how your tumours are responding. Scans will check both your chest and your brain. You will be followed up for at least two years so the team can monitor how long the treatment works and support your health.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What is ALK-positive lung cancer?
It is a type of non-small cell lung cancer caused by a change in a gene called ALK. This change sends signals that make cancer cells grow. Targeted drugs are designed to block this signal.
What is a liquid biopsy?
A liquid biopsy is a simple blood test that looks for tiny pieces of tumour DNA circulating in your blood. It gives doctors clues about how the cancer is changing without needing a tissue biopsy.
How is the trial medication taken?
Brigatinib comes as film-coated tablets that you swallow once a day with water, usually at home.
Will taking part cost me anything?
No, the study medication and extra trial tests are provided free of charge. Some trials also help with travel expenses to hospital visits.
Can I leave the trial if I change my mind?
Yes, you can leave the study at any time for any reason. Your decision will not change the quality of medical care you receive from the NHS.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.